Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Advances in the understanding of the pathogenesis and epidemiology of herpes zoster.

Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD.

J Clin Virol. 2010 May;48 Suppl 1:S2-7. doi: 10.1016/S1386-6532(10)70002-0. Review.

2.

Pathogenesis and current approaches to control of varicella-zoster virus infections.

Gershon AA, Gershon MD.

Clin Microbiol Rev. 2013 Oct;26(4):728-43. doi: 10.1128/CMR.00052-13. Review.

3.

Latency of varicella zoster virus; a persistently perplexing state.

Kinchington PR.

Front Biosci. 1999 Feb 15;4:D200-11. Review.

PMID:
9989948
4.

The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review.

Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF.

J Infect Dis. 2008 Mar 1;197 Suppl 2:S224-7. doi: 10.1086/522162. Review.

PMID:
18419401
5.

[Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics].

Wittek M, Doerr HW, Allwinn R.

Med Klin (Munich). 2010 May;105(5):334-8. doi: 10.1007/s00063-010-1061-3. Epub 2010 May 26. Review. German.

PMID:
20503007
6.

[Reactivation of herpes zoster infection by varicella-zoster virus].

Cvjetković D, Jovanović J, Hrnjaković-Cvjetković I, Brkić S, Bogdanović M.

Med Pregl. 1999 Mar-May;52(3-5):125-8. Review. Croatian.

PMID:
10518396
7.

Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency.

Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA.

Neurol Clin. 2008 Aug;26(3):675-97, viii. doi: 10.1016/j.ncl.2008.03.011. Review.

8.

Immune evasion as a pathogenic mechanism of varicella zoster virus.

Abendroth A, Arvin AM.

Semin Immunol. 2001 Feb;13(1):27-39. Review.

PMID:
11289797
9.

Varicella-zoster virus: overview and clinical manifestations.

Arvin AM.

Semin Dermatol. 1996 Jun;15(2 Suppl 1):4-7. Review.

PMID:
8840410
10.

Varicella-zoster virus neurotropism in SCID mouse-human dorsal root ganglia xenografts.

Zerboni L, Reichelt M, Arvin A.

Curr Top Microbiol Immunol. 2010;342:255-76. doi: 10.1007/82_2009_8. Review.

PMID:
20225014
11.

Varicella-zoster virus latency in human ganglia.

Kennedy PG.

Rev Med Virol. 2002 Sep-Oct;12(5):327-34. Review.

PMID:
12211045
12.

The neurotropic herpes viruses: herpes simplex and varicella-zoster.

Steiner I, Kennedy PG, Pachner AR.

Lancet Neurol. 2007 Nov;6(11):1015-28. Review.

PMID:
17945155
13.

The variegate neurological manifestations of varicella zoster virus infection.

Gilden D, Nagel MA, Cohrs RJ, Mahalingam R.

Curr Neurol Neurosci Rep. 2013 Sep;13(9):374. doi: 10.1007/s11910-013-0374-z. Review.

14.

Varicella-zoster virus.

Arvin AM.

Clin Microbiol Rev. 1996 Jul;9(3):361-81. Review.

15.

Varicella-zoster virus and virus DNA in the blood and oropharynx of people with latent or active varicella-zoster virus infections.

Levin MJ.

J Clin Virol. 2014 Dec;61(4):487-95. doi: 10.1016/j.jcv.2014.09.012. Epub 2014 Oct 2. Review.

PMID:
25453570
16.

Herpes zoster and postherpetic neuralgia.

Johnson RW.

Expert Rev Vaccines. 2010 Mar;9(3 Suppl):21-6. doi: 10.1586/erv.10.30. Review.

PMID:
20192714
17.

A comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivation.

Kennedy PG, Rovnak J, Badani H, Cohrs RJ.

J Gen Virol. 2015 Jul;96(Pt 7):1581-602. doi: 10.1099/vir.0.000128. Epub 2015 Mar 20. Review.

18.

Molecular studies of Varicella zoster virus.

Quinlivan M, Breuer J.

Rev Med Virol. 2006 Jul-Aug;16(4):225-50. Review.

PMID:
16791838
19.

The impact of varicella zoster virus: chronic pain.

Opstelten W, McElhaney J, Weinberger B, Oaklander AL, Johnson RW.

J Clin Virol. 2010 May;48 Suppl 1:S8-13. doi: 10.1016/S1386-6532(10)70003-2. Review.

PMID:
20510265
20.

Supplemental Content

Support Center